AWARD NUMBER: W81XWH-13-1-0257

TITLE: Coregulation of srGAP1 by Wnt and Androgen Receptor Signaling: A New Target for Treatment of CRPC

PRINCIPAL INVESTIGATOR: Noriko Yokoyama

CONTRACTING ORGANIZATION: University of California
Irvine, CA 92617

REPORT DATE: October 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Androgen receptor (AR) and Wnt signaling both play a critical role during prostate cancer progression to castration-resistance prostate cancer (CRPC). Over expression of AR can activate transcriptional activities of Wnt signaling pathway and promote CRPC. Recent data in our laboratory showed a potential co-regulation of srGAP1 (Slit-Robo-GTPase activating protein1) and active Wnt and AR signaling in CRPC. srGAP1 is a downstream component of Slit-Robo signaling. Our data showed that srGAP1 is overexpressed in CRPC cell lines (androgen-insensitive prostate cancer) while absent in both androgen-sensitive cells and in normal prostate epithelial cells. We also detected increased srGAP1 and LEF-1 expression in human CRPC tissues compared with normal epithelial prostate and androgen sensitive prostate cancer tissues by immunohistochemistry analysis. When androgen-sensitive LNCaP cells were grown under androgen deprived condition, we observed induced expression of srGAP1. Interestingly, srGAP1 expression was also increased when LNCaP cells were grown under Wnt stimulated conditions. And, srGAP1 expression was decreased when Wnt signaling was inhibited by a Wnt antagonist Wnt-inhibitory factor-1 (WIF-1) in CRPC cell lines. Chromatin immunoprecipitation assay was performed to examine whether Wnt transcription factor TCF-4 binds to the srGAP1 promoter. Overexpression of WIF-1 inhibited the promoter activity of srGAP1. Taken together, our results indicated that srGAP1 is co-regulated by both Wnt and AR signaling and srGAP1 may be a new potential Wnt target gene in castration-resistance prostate cancer.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. INTRODUCTION</td>
<td>4</td>
</tr>
<tr>
<td>2. KEYWORDS</td>
<td>4</td>
</tr>
<tr>
<td>3. ACCOMPLISHMENTS</td>
<td>4 - 12</td>
</tr>
<tr>
<td>4. IMPACT</td>
<td>12</td>
</tr>
<tr>
<td>5. CHANGES/PROBLEMS</td>
<td>12 - 13</td>
</tr>
<tr>
<td>6. PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS</td>
<td>13</td>
</tr>
<tr>
<td>7. PARTICIPANTS &amp; OTHER COLLABORATING ORGANIZATIONS</td>
<td>11</td>
</tr>
<tr>
<td>8. SPECIAL REPORTING REQUIREMENTS</td>
<td>13</td>
</tr>
<tr>
<td>9. APPENDICES</td>
<td>13</td>
</tr>
<tr>
<td>i. CV</td>
<td>14 - 18</td>
</tr>
<tr>
<td>ii. Published manuscript</td>
<td>19 - 36</td>
</tr>
</tbody>
</table>
1. INTRODUCTION:

Prostate cancer is one of the most common cancer diagnosed in the United States and advanced staged prostate cancer especially patients who develop resistance to androgen deprivation therapy, known as castration-resistance prostate cancer (CRPC), is one of the leading causes of death in males. In the recent years, researchers have discovered that androgen receptor (AR) and Wnt signaling both play a critical role during prostate cancer progression to CRPC. Over expression of AR can activate transcriptional activities of Wnt signaling pathway and promote CRPC. Our laboratory discovered a potential co-regulation of srGAP1 (Slit-Robo-GTPase activating protein1) and active Wnt and AR signaling in CRPC cell lines. srGAP1 is a downstream component of Slit-Robo signaling. Our data showed that srGAP1 is overexpressed in CRPC cell lines (22Rv1, C4-2B, PC3, PC3M, PC3/LN4) while absent in both androgen-sensitive cells and in normal prostate epithelial cells. Aside from our study there are no other reports linking srGAP1 and prostate cancer. In this report we summarize new studies and findings of srGAP1 in prostate cancer and linking Wnt and the Slit-Robo signaling pathway through identification of srGAP1 as a Wnt target. Our goal is to identify srGAP1 and Slit-Robo pathway as a new target and develop a novel treatment for CRPC.

2. KEYWORDS:

CRPC, AR, srGAP, Robo1, Wnt, WIF1, GTPases, LEF-1, Androgen

3. ACCOMPLISHMENTS:

Major Tasks and accomplishments are listed under these goals

Specific Aim 1: Test the hypothesis that srGAP1 is a target gene of Wnt signaling and regulated by AR signaling in CRPC.

1) Chromatin Immunoprecipitation (ChIP) assays were carried out to examine LEF-1 binding to Wnt response element on the 5' promoter region of srGAP1 gene. There are three potential LEF/TCF transcription factor binding sites approximately 2.8kb upstream of srGAP1 coding region (Figure 1A). All LEF/TCF transcription factors can recognize and bind to the same consensus sequence YCTTTGWW. We performed ChIP to examine whether TCF4 transcription factor can bind to 5' promoter region of SRGAP1 gene. ChIP assay was performed using CRPC cell lines PC3 whether endogenous TCF-4 binds to the SRGAP1 promoter. Primer set that detects all three LEF/TCF binding of the 5' promoter region of SRGAP1 was used to perform PCR and real time PCR. We observed that TCF-4 binds to the SRGAP1 promoter (Figure 1B). We also performed ChIP assay using PC3 stable cells that overexpresses Wnt inhibitors WIF-1 and Frzb. TCF-4 binds to the SRGAP1 promoter in the absence of Wnt inhibitors, whereas, TCF-4 occupancy was decreased in the presence of Wnt inhibitors (Figure 1C). ChIP data strongly suggest that srGAP1 expression is regulated by Wnt signaling.
A.  

```
5'  
TATTTCTATCTCTTTACAGCATTTATTGTACTGCTTGTAATTATTTATTTATACAGTAATAGAC  
TGCATGATCCTTTCCGCACTTTATAATCTTG  
TCCCTAGTTCCTAGCGTGGTGTTTG  
CACAGAGTTAAAGAAGCTGGAGAGCCGATCACTGGATACATGAAAGAATGATCAAAGTCTGGAAAAGTCCTACTTTCTTTAGATCTTGTGGGGAAAACACTTGAGGGAGTACAACCTTTGG
```

B.  

![Image of PCR gel](image)

**Figure 1. TCF-4 binds to SRGAP1 promoter.**  
**A)** Three potential LEF/TCF transcription factor binding sites approximately 2.8kb upstream of srGAP1 coding region.  
**B)** ChIP was performed to assess whether endogenous TCF-4 binds to the SRGAP1 promoter in PC3 cells.  
**C)** ChIP followed by qPCR was performed for PC3/pDNA3.1(control) and PC3 overexpressed with Wnt inhibitors WIF-1 and Frzb. TCF-4 bound to the SRGAP1 promoter in the absence of Wnt inhibitors, whereas, TCF-4 occupancy was decreased in the presence of Wnt inhibitors.

2) Immunohistochemistry was performed to examine co-expression of srGAP1 and LEF1 in human prostate cancer tissues. We examined srGAP1 expression in human prostate cancer tissues for both androgen sensitive PCa and CRPC. We detected more srGAP1 expression in CRPC tumor tissues compared to androgen sensitive PCa tissues (Figure 2A). We also performed immunohistochemistry to examine LEF-1 expression as well. LEF-1 is also expressed more in CRPC tumor tissues compared to androgen sensitive PCa (Figure 2B).
3) The transcription regulation of srGAP1 in prostate cancer cells was studied under Wnt and androgen stimulated conditions. We looked to compare expression patterns for srGAP1 and LEF-1 expression in LNCaP (androgen sensitive PCa), LNCaP-AI (a derivative of LNCaP cells from long term androgen deprivation), and LNCaP-LEF1 (LNCaP cells overexpressing LEF-1). Protein expression shown by Western blot analysis show that LEF-1 transcription factor have higher expression in androgen-insensitive prostate cancer (LNCaP-AI and LNCaP-LEF1) compared to androgen sensitive prostate cancer (LNCaP) (Figure 3A). We also looked at protein and RNA expression pattern of srGAP1 in androgen sensitive PCa cells grown under androgen deprivation conditions (Figure 3B). LNCaP cells were cultured under 10% cFBS condition for seven days. At the last 24 hours, synthetic androgen (R1881) were added different concentrations. Both Western and real-time PCR result show that different androgen levels in the medium can regulate srGAP1 expression. Furthermore, we looked at srGAP1 expression levels in PC3 and C4-2B (androgen insensitive) cells overexpressing Wnt inhibitors WIF1 and Frzb (Figure 3C). We detected significant reduction of srGAP1 expression in both protein and RNA levels which indicates that Wnt signaling is involved in controlling expression levels of srGAP1 in CRPC.
Specific Aim 2: Test the hypothesis that down regulating srGAP1 in CRPC cells change phenotypic characteristics and reverse tumorigenesis and metastasis.

1) Stably transfected srGAP1 expression in PC3 CRPC cells using shRNA was used to examine cell growth assay. Figure 4A shows Western blot analysis of srGAP1 protein expression of PC3 cells knockdown with control shRNA and srGAP1 shRNA. Cell proliferation assay (also known as MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) Assay) was conducted with both control shRNA and srGAP1 shRNA to compare for cell viability and proliferation during 72hrs of cell growth. srGAP1 knockdown cells inhibited cell growth by about 50% compared to the native PC3 and shCtrl-PC3 cells during 72 hrs growth period.

Figure 3. srGAP1 is regulated by both androgen and Wnt signaling.

A) Western blot analysis of srGAP1 and LEF-1 expression in LNCaP, LNCaP-AL, and LNCaP-LEF1 cells.

B) Western blot (left) and RT-realtime PCR (right) analysis of srGAP1 expression of protein and mRNA respectively in LNCaP cells. LNCaP cells were cultured under 10% cFBS condition for seven days. At the last 24 hours, synthetic androgen (R1881) were added at the indicated concentrations.

C) Western blot analysis (left) of srGAP1 protein expression in PC3 and C4-2B cell lines with stable expression of vector control (pcDNA3.1) or WIF1 Wnt inhibitor. RT-realtime PCR (right) analysis of srGAP1 mRNA expression PC3 and C4-2B cell lines with stable expression of vector control, WIF1 or Frzb.
Figure 4. Knockdown of srGAP1 by shRNA induces significant morphological changes leading to inhibition of cell growth and migration in PC3 cells.

A) Western blot analysis of srGAP1 protein expression of PC3 cells stably transfected with scrambled control shRNA and srGAP1 shRNA.  

B) PC3 cells with knockdown control shRNA and srGAP1 shRNA were grown for three days for cell viability assay. Cell viability was measured by the MTT assay.  

C) shCtrl and shsrGAP1 knockdown cells were examined for cell motility by using migration membrane chambers and Matrigel-coated invasion chambers. Number of migrated cells were counted and percent of shsrGAP1 cells were compared over shCtrl PC3 cells.
2) Migration and matrigel invasion assay was conducted to examine PC3-shCtrl and PC3-shsrGAP1 cells ability to migrate and invade across Matrigel. Cell motility was tested by PC3-shCtrl and shsrGAP1 PC3 cells ability to migrate through membrane chamber after 24hrs. In vitro invasiveness of PC3-shCtrl and shsrGAP1 PC3 cells were tested by how efficiently the cells invade through a Matrigel-coated membrane after 48hrs. Consistent with our migration data we observed a decrease in invasive capacity of srGAP1 knocked-down cells compared to the control cells (Fig 4C).

3) In vivo mouse tumor model study using PC3-shCtrl and PC3-shsrGAP1 cells. IRB and IACUC paper work were approved for mice study. Mouse handling and surgery training through UCI’s ULAR program was completed.

4) PC3-shCtrl and two different stable PC3-shsrGAP1 cells were injected in to nude mice. Mice were monitored weekly for tumor growth. After 12 weeks, all mice were weighed and sacrificed. However, none of the mice seemed to grow tumor even the control PC3 cells which should have produced tumor. The conclusion from the initial mice study was inconclusive. Since originally proposed cell line PC3 and C42B prostate cancer cells did not produce a good orthotopic mice prostate tumor models despite attempting several times. We decided to use another more aggressive prostate cancer cell lines PC3M-LN4 which is still CRPC cells. We requested for no-cost extension before the project end date in August (08/27/2015) with new tasks and deadline. The request was approved the second week of December 2015 and more details are written in section 5 below under CHANGES/PROBLEMS.

Accomplishment during no-cost extension period
1) We used lentivirus shRNA knockdown method to stably knockdown srGAP1 expression in PC3M-LN4 (CRPC) cell lines. Figure 5A shows Western blot analysis of srGAP1 protein expression of PC3M-LN4 cells compared with control shRNA (shCtrl) and two different srGAP1 knockdown stable cell lines. New srGAP1 knockdown cells were tested for cell proliferation, migration, cell invasion assay, and soft agar colony assay comparing to the control cell lines.

2) Cell proliferation assay was conducted with both control shRNA and srGAP1 shRNA to compare for cell viability and proliferation at 72, 120, and 168 hrs of cell growth (Figure 5B). srGAP1 knockdown cells inhibited cell growth by over 40% compared to the control PC3M-LN4 cells during 120 hrs growth period.

3) We next performed migration and invasion assay to examine PC3M-LN4-shCtrl and PC3M-LN4 shsrGAP1 cells ability to migrate and invade across Matrigel (Figure 6A). Cell motility was tested by PC3M-LN4-shCtrl and shsrGAP1 cell's ability to migrate through membrane chamber after 24hrs. In vitro invasiveness of shCtrl and shsrGAP1 of PC3M-LN4 cells were tested by how efficiently the cells invade through a Matrigel-coated membrane after 48hrs. Invasion index percentage was calculated by subtracting number of cells migrated through uncoated membrane from cells invaded through matrigel coated membrane multiply by 100. We observed a decrease in invasive capacity of srGAP1 knocked-down cells compared to the control cells (Figure 6A).

4) Finally we tested these shsrGAP1 knockdown cells for anchorage-independent growth assay by growing control and knockdown cells in soft agar plates. Representative image of soft agar colony formed cells are shown in Figure 6B. Knockdown of srGAP1 inhibited about...
80% colony formation compared to control PC3M-LN4(Figure 6C). All of the above data suggested that knocking down srGAP1 decreases invasiveness of PC3M-LN4 cells.

Figure 5. Knockdown of srGAP1 by shRNA decreases cell growth in PC3M-LN4 cells.
A) Western blot analysis of srGAP1 protein expression of PC3M-LN4 cells stably transfected with control shRNA and srGAP1 shRNA.
B) PC3M-LN4 cells with knockdown control shRNA and srGAP1 shRNA were grown for three, five, and seven days for cell viability assay. Cell viability was measured by the MTT assay.
Figure 6. Knockdown of srGAP1 inhibits cell invasion and decreases anchorage independent colony formation in PC3M-LN4 cells.
A) shCtrl and shsrGAP1 knockdown cells were examined for cell motility by using migration membrane chambers and Matrigel-coated invasion chambers. Number of migrated cells were substracted from invaded cells and percent of shsrGAP1 cells were compared over shCtrl PC3M-LN4 cells.
B) Representative image of soft agar colony formation is shown.
C) Qualitative analysis of soft agar colony formation between PC3M-LN4 Ctrl and srGAP1 knockdown cells are shown.
Training and professional development tasks

- I have presented research in progress and discussion of my project during meetings with my mentors throughout this reporting period.

- I have attended one week Stem Cell Techniques Course hosted by Sue and Bill Gross Stem cell Research center at UCI January of 2014.

- I have attended annual American Association for Cancer Research (AACR) conference in San Diego 2014 and submitted my abstract. Research poster was presented at this conference.

- I have attended one day workshop for discovery of Metabolomics hosted by Metabolon, Inc. in September of 2014.

- I have attended Epigenetics conference hosted by the Center for Epigenetics and Metabolism at UCI in January of 2015.

- I have attended seminar and lecture series hosted by Chao Family Comprehensive Cancer Center at UCI throughout this reporting period.

- I have also presented my research progress of this project at Cancer Biology Journal club, Cancer Research Institute at UCI November of 2014.

Goals for the next reporting period

For the next reporting period, I will be finishing up the In vivo mouse tumor model study using PC3M-LN4-shCtrl and PC3M-LN4-shsrGAP1 cells. Early December of 2015 I performed orthotopic prostate cancer surgery in mice. Currently monitoring mice for tumor growth. Once PC3M-LN4 tumor bearing mice are terminated, wet weight of the tumor will be documented as well as organ and tumor status. Harvested tissues will be characterized by pathology and histology studies.

4. IMPACT:
Nothing to report at this time

5. CHANGES/PROBLEMS:

Due to unforeseen technical challenges in growing tumors in mice using PC3 prostate cancer cells lines, no-cost extension was requested before the end of the funding period in August of 2015. No-cost extension was recently approved in December of 2015. The new end date will be March 15, 2016.

Current and remaining work to be completed during the period of non-cost extension is listed below:

**Task 1.** The originally proposed cell line PC3 prostate cancer cells did not produce a good orthotopic mice prostate tumor models despite attempting several times. We decided to use another more aggressive prostate cancer cell lines PC3M-LN4. Making of a new stable cell lines with srGAP1 shRNA knockdown model took 4 months. We tested these new knockdown cells for cell proliferation, migration, and cell invasion assay comparing to the control cell lines (results shown Figure 5 and 6 above).
Task 2. New PC3M-LN4 control and PC3M-LN4 srGAP1 knockdown cell are used for orthotopic prostate cancer surgery in mice. Growing and monitoring of tumor growth may take several months.

Task 3. Once PC3M-LN4 tumor bearing mice are terminated, wet weight of the tumor will be documented as well as organ and tumor status. Harvested tissues will be characterized including pathology and histology. Statistical analysis will be performed.

6. PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:

1) Manuscript published

2) Abstract submission at AACR April 2014 conference.
Yokoyama, N.N., Sakai, T., Sun, Z., Shao, S., Huang, J., Hoang, B.H., and Zi, X. Co-regulation of srGAP1 by Wnt and androgen receptor signaling in castration resistant prostate cancer. AACR conference 2014, San Diego, CA

3) Presentation at Cancer Biology Journal club, Cancer Research Institute, University of California, Irvine. 2014

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS:

PI: Noriko Yokohama
Project Role: Postdoctoral fellow, main researcher on this grant.
No other participants and collaborators on this project.

8. SPECIAL REPORTING REQUIREMENTS:
Nothing to report

9. APPENDICES:
Curriculum Vitae

Noriko N Yokoyama

Personal Information:

Address: 101 The City Drive South
Bldg. 55 Rm. 360
Orange, CA 92868
Phone: (714) 456-6088
E-mail Address: nyokoyam@uci.edu

Education:

1997-2001 University of Texas at Austin
Bachelor of Science in Molecular Biology

2001-2003 University of California, Irvine
Master of Science in Biotechnology

2003-2009 University of California, Irvine
Doctor of Philosophy in Biological Sciences

Research Experience:

1996 Student Research with Annette Fo thergill, Pathology Department of Fungus Testing Lab.
University of Texas Health Science Center San Antonio, Texas

2000-2001 Undergraduate Research with Professor Paul J. Szaniszlo Ph.D.,
Department of Microbiology
University of Texas at Austin

2001-2003 Masters graduate research with Professor Michael Cumsky Ph.D.,
Department of Molecular Biology and Biochemistry
University of California, Irvine

2002-2003 Associate Intern at Allergan Pharmaceuticals with Peter Baciu Ph.D.,
Research and Development, Department of Biology
Irvine, California

2003 Predoctoral Graduate Research with Professor David Camerini Ph.D.,
Department of Molecular Biology and Biochemistry
University of California, Irvine
2004-2009 Predoctoral Graduate Research with Professor Marian L. Waterman Ph.D., Department of Microbiology and Molecular Genetics University of California, Irvine

2009-2010 Junior Specialist with Professor Marian L. Waterman Ph.D., Department of Microbiology and Molecular Genetics University of California, Irvine

2012-Present Postdoctoral fellow with Professor Xiaolin Zi Ph.D., MD, Department of Urology University of California Irvine Medical Center, Orange

Teaching Experience:

2003 Teaching Assistant, Genetic engineering/Biotechnology (Mol Bio 228), University of California, Irvine

2003-2004 Teaching Assistant, Biotech Nucleic acid (Mol Bio 250L) and Biotech Protein (Mol Bio 251L), Laboratory, University of California, Irvine

2007 Grading assistant, Regulation of Gene Expression (Mol Bio 206), University of California, Irvine

Academic-Related Service and Fellowship awards:

2003-2004 MBGB (Molecular Biology, Genetics, and Biochemistry) Fellowship, University of California, Irvine

2005-2006 Student Representative, Department of Microbiology and Molecular Genetics, University of California, Irvine

2007 Dr. William F. Holcomb Scholarship for outstanding research in Biomedical Science

2007-2008 NIH Training grant entitled “Translational Research in Cancer Genomic Medicine”

Professional membership

2012-2015  American Association for Cancer Research (AACR)

Patent:

2004  "Mouse cell lines for CCR5, CCR7".  University of California Invention.  

Seminar Presentations:

2004  Yokoyama, N.N. Activation and Repression of LEF1 Promoters in Colon Cancer.  
Gene Expression seminar series, University of California, Irvine

2006  Yokoyama, N.N. LEF1 gene regulation and expression in Colon cancer.  
Microbiology & Molecular Genetics Departmental Seminar, University of California, Irvine

2007  Yokoyama, N.N. Repression of the LEF1 Alternative Promoter in Colon cancer.  
Microbiology & Molecular Genetics Departmental Seminar, University of California, Irvine

2008  Yokoyama, N.N. Repression of the LEF1 Alternative Promoter in Colon cancer.  
Microbiology & Molecular Genetics Departmental Seminar, University of California, Irvine

2009  Yokoyama, N.N. Repression of the LEF1 Alternative Promoter in Colon cancer.  
Doctoral thesis defense, University of California, Irvine

2013  Guest Speaker for the RCP (Research Careers Prep) Program  
Cal State Fullerton (CSUF)

2014  Yokoyama, N.N. Co-regulation of srGAP1 by Wnt and androgen receptor signaling in castration resistant prostate cancer. Cancer Biology Journal club, Cancer Research Institute, University of California, Irvine

Poster Presentations:

2001  Yokoyama, N.N., Liu, H., Starvrou, I., and Szaniszlo P.J. Constructing Double Disruption Mutants of WdCHS, a Gene that Encodes Chitin Synthase in Wangiella dermatitidis. Undergraduate research presentation, University of Texas at Austin

2005 Yokoyama, N.N., Li, T. W.-H., and Waterman, M.L. Activation and Repression of LEF1 Promoters in Colon Cancer. BSDB meeting, Wnt signaling in Development, Disease, and Cell Biology, Aberdeen, University of Aberdeen

2006 Yokoyama, N.N., Li, T. W.-H., Ting, J.-H. T., and Waterman, M.L. Repression of the LEF1 Alternative Promoter in Colon Cancer. Keystone Symposia, Wnt and Beta-Catenin Signaling in Development and Disease, Snowbird Resort, Snowbird Utah

2006 Yokoyama, N.N., and Waterman, M.L. Repression of the LEF1 Alternative Promoter in Colon Cancer. Microbiology & Molecular Genetics Departmental Research Retreat, Lake Arrowhead, CA


2007 Yokoyama, N.N., Li, T. W.-H., Pate, K., Ko, A., Ranheim, E., and Waterman, M.L. Repression of the LEF1 Alternative Promoter in Colon Cancer. Wnt Signaling in Development and Disease. Max Delbruck Center for Molecular Medicine, Berlin-Buch, Germany

2013 Yokoyama, N.N., Sun, Z., Sakai, T., Hoang, B. H., and Zi, X. Robo1, a new target, is regulated by Wnt and androgen receptor signaling in castration resistant prostate cancer. AACR conference, Washington D.C.

2014 Yokoyama, N.N., Sakai, T., Sun, Z., Shao, S., Huang, J., Hoang, B.H., and Zi, X. Co-regulation of srGAP1 by Wnt and androgen receptor signaling in castration resistant prostate cancer. AACR conference, San Diego, CA

Publications:


Review Article

Wnt signaling in castration-resistant prostate cancer: implications for therapy

Noriko N Yokoyama¹, Shujuan Shao¹, Bang H Hoang², Dan Mercola⁴,⁵,⁶, Xiaolin Zi¹,²,³,⁴

Departments of ¹Urology, ²Pharmaceutical Sciences, ³Pharmacology, ⁴Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA 92868, USA; ⁵Department of Orthopaedic Surgery, University of California, Irvine, Orange, CA 92868, USA; ⁶Department of Pathology and Laboratory Medicine, University of California, Irvine, Orange, CA 92868, USA

Received March 9, 2014; Accepted March 26, 2014; Epub April 5, 2014; Published April 15, 2014

Abstract: Increasing evidence has indicated that Wnt signaling plays complex roles in castration resistant prostate cancer (CRPC). Although not all data were consistent, β-catenin nuclear localization and its co-localization with androgen receptor (AR) were more frequently observed in CRPC compared to hormone naïve prostate cancer. This direct interaction between AR and β-catenin seemed to elicit a specific expression of a set of target genes in low androgen conditions in CRPC. Paracrine Wnt signaling also was shown to aid resistance to chemotherapy and androgen deprivation therapy. Results from the next generation sequencing studies (i.e. RNA-seq and whole exosome sequencing) of CRPC specimens have identified the Wnt pathway as one of the top signaling pathways with significant genomic alterations in CRPC, whereas, Wnt pathway alterations were virtually absent in hormone naïve primary prostate cancer. Furthermore, Wnt signaling has been suggested to play an important role in cancer stem cell functions in prostate cancer recurrence and resistance to androgen deprivation therapy. Therefore, in this review we have summarized existing knowledge regarding potential roles of Wnt signaling in CRPC and underline Wnt signaling as a potential therapeutic target for CRPC. Further understanding of Wnt signaling in castration resistance may eventually contribute new insights into possible treatment options for this incurable disease.

Keywords: Wnt signaling, castration-resistant prostate cancer, targeted therapy

Introduction

Prostate cancer is a biologically diverse disease. A significant proportion of elderly men with this disease are asymptomatic [1, 2]. Most of these asymptomatic cases are prostate cancers which may be managed by watchful waiting and active surveillance. Prostate cancer patients who have clinically localized disease at diagnosis often receive curative treatments through radical prostatectomy or radiotherapy. However, between 20% and 40% of these patients eventually experience biochemical recurrence [3, 4]. Patients with biochemically recurrent disease, metastatic prostate cancer, and locally advanced prostate cancer are then mainly treated with androgen deprivation therapy (ADT). Since the 1940s, ADT consists of surgical or medical castration method to reduce circulating androgens [5]. Unfortunately, all patients eventually develop resistance to ADT called castration-resistant prostate cancer (CRPC) [6]. Recently, two new FDA approved drugs (i.e. Abiraterone Acetate and Enzalutamide) more effectively block androgen synthesis and to prevent activation of androgen receptor (AR) [7, 8]. Although these AR targeting agents extend life of CRPC patients by a few months, resistance to these treatments remains common and currently there is no cure for CRPC [9-18]. Therefore, understanding the molecular mechanisms leading to CRPC and identifying alternative targets are important in developing more effective treatment for CRPC.

Much new evidence summarized here indicates that the Wnt signaling pathway is one of the major pathways that are involved in developing CRPC. The Wnt pathway plays a central role in the development of many tissues and organs [19]. Aberrant activation of the Wnt/β-catenin pathway contributes to the progression of sev-
eral major human cancers, including colorectal, liver and prostate cancer [19]. Evidence has accumulated that the Wnt/β-catenin pathway plays an important role in CRPC by interacting with AR signaling [20-33]. Recent studies using next-generation sequencing of CRPC tumors have revealed significant genomic alterations in multiple components of the Wnt pathway, whereas, alterations of the Wnt pathway in hormone treatment naïve prostate cancer were viturally undetectable [34, 35]. Moreover, it has been reported that aberrant paracrine Wnt signaling from prostatic stroma can also contribute to the resistance to ADT before or after chemotherapy [36, 37]. Hence, the main goal of this review is to summarize the important role of the Wnt/β-catenin in progression to CRPC and discuss potential therapeutic approaches for targeting the Wnt pathway for treatment of CRPC. Proposed mechanisms for elevated Wnt signaling in CRPC are summarized in Table 1.

**Table 1. Proposed mechanisms for elevated Wnt signaling in CRPC**

<table>
<thead>
<tr>
<th>Mechanisms</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuclear β-catenin localization</td>
<td>[32, 41]</td>
</tr>
<tr>
<td>AR/β-catenin interaction</td>
<td>[26, 32, 35, 68]</td>
</tr>
<tr>
<td>LEF1 overexpression</td>
<td>[83]</td>
</tr>
<tr>
<td>Crosstalk between β-catenin and AKT, HIF-1α and others</td>
<td>[69-75]</td>
</tr>
<tr>
<td>Overexpression of Wnt ligands and receptors</td>
<td>[23, 94-106]</td>
</tr>
<tr>
<td>Paracrine Wnt signaling</td>
<td>[36, 37, 91-93]</td>
</tr>
<tr>
<td>Loss of secreted Wnt antagonists</td>
<td>[136]</td>
</tr>
<tr>
<td>Epithelial to mesenchymal transition</td>
<td>[123, 124, 137]</td>
</tr>
<tr>
<td>Cancer stem cells</td>
<td>[134]</td>
</tr>
</tbody>
</table>

β-Catenin is a dual function protein and it can regulate cell-cell adhesion and gene activation [33]. A hallmark of canonical Wnt signaling is the stabilization and nuclear localization of β-catenin [19]. Therefore, various groups have studied β-catenin localization in CRPC specimens compared to hormone-naïve prostate cancer (Table 2). Chesire et al. [40] reported that about 24% (5/21) of metastatic tumors from various anatomical sites of autopsy samples from CRPC patients were positive for β-catenin nuclear localization. de la Taille et al. [41] evaluated β-catenin expression by immunohistochemistry staining in 212 prostate cancer specimens, including 122 localized prostate cancer from prostatectomy specimens and 90 from CRPC specimens from transurethral resections of the prostate due to bladder obstruction. Abnormal β-catenin expression was defined as cytoplasmic and/or nuclear staining. In this study, about 23% of radical prostatectomy specimens exhibited abnormal β-catenin expression compared to 38.8% of metastatic CRPC cases with statistically significant result of $p = 0.042$. Likewise, Patriarca et al. [42] found that β-catenin levels were also elevated in 20 acinar prostatic adenocarcinomas after anti-androgen therapy in prostatectomy specimens compared to that of pretreatment biopsies of the same patient group and high Gleason grade, matched and untreated controls. Wan et al. [32] also found nuclear localization of β-catenin in 11 of 27 (40.7%)
Table 2. Nuclear β-catenin localization in CRPC and hormone naïve prostate cancer

<table>
<thead>
<tr>
<th>Sources</th>
<th>Percentage of positive staining</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metastatic tumors from autopsy</td>
<td>24% (5/21), nuclear</td>
<td>[40]</td>
</tr>
<tr>
<td>CRPC from TURP</td>
<td>38.8% (35/90), nuclear</td>
<td>[41]</td>
</tr>
<tr>
<td>CRPC bone metastases</td>
<td>40.7% (11/27), nuclear</td>
<td>[43]</td>
</tr>
<tr>
<td>CRPC matched pairs</td>
<td>55% (16/29), nuclear and cytoplasmic</td>
<td>[35]</td>
</tr>
<tr>
<td>Localized PCa from RP</td>
<td>23% (49/212), nuclear</td>
<td>[41]</td>
</tr>
<tr>
<td>Localized PCa from RP</td>
<td>18% (39/186), nuclear</td>
<td>[50]</td>
</tr>
</tbody>
</table>

PCa: prostate cancer; RP: radical prostatectomy; CRPC: castration resistant prostate cancer; TURP: transurethral resections of the prostate.

CRPC bone metastases. Eight (29.6%) of 27 specimens exhibited both β-catenin and androgen receptor positive staining in the nuclei compared to only 3 (11.1%) of the 27 specimens exhibited β-catenin nuclear staining positive when AR was undetectable indicating that more nuclear β-catenin was present in AR-positive nuclei in CRPC tissues. Rajan et al. [35] detected β-catenin protein over-expression in 16 CRPC of 29 matched pairs of hormone-naïve PCa (HNPC) and CRPC; they also found a statistically significant correlation between β-catenin and nuclear AR protein expression in CRPC but not in HNPC. Chen et al. [43] observed 55% (34 out of 62) of primary prostate and 85% (20 out of 23) of prostate carcinoma metastases to lymph nodes and bone specimens with cytoplasmic and nuclear β-catenin expression, respectively. Additionally, Aaltomaa et al. [44] showed that only 18% (39 out of 186) of prostate cancer specimens from radical prostatectomy were positive nuclear β-catenin. Finally, Jung et al. [45] reported that ADT-treated patients who exhibited short times to PSA progression expressed higher levels of MMP-7. The expression of cytoplasmic β-catenin, MMP-7, and AR was positively correlated.

In the above section, we summarized studies that reported increased expression of nuclear β-catenin in CRPC; however, there were other groups that observed an opposite trend. Assikis et al. [46] examined β-catenin expression on a tissue microarray from 16 patients who underwent salvage surgery for symptomatic, locally aggressive androgen-independent prostate cancer and found no nuclear β-catenin expression in these specimens. Whitaker et al. [47] also examined for nuclear β-catenin staining in that were most likely from hormone naïve patients. Bismar et al. did not detect any nuclear β-catenin staining in 101 prostatic adenocarcinomas, including 72 acinar and 29 ductal, and 16 cases of high-grade prostatic intraepithelial neoplasia (HPIN) using identical immunostaining procedures [48]. Membranous β-catenin act primarily as a cell adhesion molecule. The loss of membranous β-catenin in a small fraction of prostatic adenocarcinomas with higher Gleason scores was found in this study compared to normal prostatic epithelium. This result suggests a differential mechanism of β-catenin from its role as a cofactor for TCF/LEF or AR. Jaggi et al. [49] also examined 17 samples of prostate cancer specimens and found a significant down-regulation of membranous β-catenin expression in prostate cancer compared to benign prostatic glands and an association with increasing Gleason grade ($p = 0.025$). In a prostate cancer prognosis study Horvath et al. [50] showed 64% (149 out of 232) of prostate cancer specimens with more than 10% of cells expressing nuclear β-catenin. However, those patients who had less than 10% of cells expressing β-catenin in the nucleus had decreased biochemical relapse-free survival times. In this study only 17.7% (41 cases) of these prostate cancer specimens were from patients with androgen deprivation therapy, therefore, this study did not separate hormone treatment naïve specimens from CRPC specimens.

In summary, the evidence suggests that there may be a role for nuclear localized β-catenin in CRPC specimens. However, the results remain conflicting. Perhaps the sample sizes and variations in the specimen processing and immunohistochemical staining methods may be contributing to the variations in the reported results.
β-catenin and androgen receptor interaction

β-Catenin contains 12 armadillo repeats in a highly conserved central region of the protein [33]. These armadillo repeats not only form a single structural unit to provide the interaction sites with APC, E-cadherin, and TCF/LEFs, but also can adopt an α-helical conformation for nuclear receptor binding proteins [33]. Using a yeast two-hybrid system, Yang et al. [26] demonstrated that β-catenin preferentially and directly bound to the ligand binding domain of AR in the presence of dihydrotestosterone (DHT) over several other steroid hormone receptors which included estrogen receptor α, progesterone receptor β, and glucocorticoid receptor. This study indicated that the NH(2) terminus and the first 6 armadillo repeats of β-catenin were required components for the AR interaction. The interaction between β-catenin and AR was further confirmed by several other studies showing that β-catenin bound to the activation function 2 region of the AR ligand binding domain and modulated the transcriptional effects of the transcriptional intermediary factor 2 (TIF2) and the AR N-terminal domain. Importantly, a single AR lysine (K720) has been shown to be necessary for the AR/β-catenin and TIF2 interactions [25, 30, 33].

The interactions between β-catenin and AR can be modulated by other cofactors through different signaling pathways in prostate cancer cells.
as well. β-Catenin interacts with AR in close proximity to the binding groove for p160 coactivators such as TIF2/glucocorticoid receptor interacting protein-1 (GRIP1) [51-54]. TIF2/GRIP1 is one of the three p160 primary coactivator proteins, which serves as a scaffold to recruit a variety of secondary coactivators, including the protein acetyltransferases p300, CBP, and coactivator-associated arginine methyltransferase (CARM1). p300/CBP and CARM1 are recruited by the p160 complex to remodel chromatin through acetylation and methylation of histones and then functions in synergy with β-catenin as coactivators for AR and TCF/LEFs [53, 54]. The methyltransferase activity of CARM1 has also been shown to be necessary for its synergistic coactivator function with β-catenin to activate AR mediated transcription [53].

ICAT (β-catenin-interacting protein 1), an inhibitor of β-catenin and TCF, can inhibit the canonical Wnt/β-catenin signaling pathway by binding to β-catenin [27]. Expression of ICAT was observed in human prostate cancer tissues and found to be elevated in xenograft tumors in castrated mice [27]. Zhou et al. [27] showed that ICAT and AR can form a ternary complex with β-catenin and stabilize the β-catenin-AR complex, which resulted in enhanced AR-mediated transcription and cell growth. The DEAD box RNA helicase p68 (Ddx5) is often overexpressed in prostate cancer tissues compared with benign tissue and studies have shown that Ddx5 is also a transcriptional coactivator for AR [55]. Interestingly, Clark et al. [56] demonstrated that the interaction between Ddx5 and β-catenin required the presence of androgens in androgen-sensitive LNCaP cells as well as other cell lines such as LNCap AI (a CRPC derivative of LNCaP cell line) when the cells are grown in the absence of androgen. Therefore, the function of Ddx5 was shown to be required for recruitment of AR and β-catenin to the promoter regions of androgen responsive genes for AR mediated transcription.

An AR variant [N-terminal truncated isoform of AR (AR45)], with an altered N-terminal domain with a replacement by a unique, short, seven amino-acid-long stretch, has been identified [57]. Overexpression of AR45 was shown to interact with the full-length AR and inhibit AR transcriptional activity and inhibit the growth of LNCaP cells [58]. However, under the conditions of β-catenin overexpression, AR45 increased dihydrotestosterone mediated AR promoter activity [58]. This result suggested that AR splicing variants may have differential effect on prostate cancer cell growth under β-catenin overexpression or overactivity.

Recent success in clinical trials of second generation of the anti-androgen drugs Abiraterone and Enzalutamide strongly support that the aberrant activation of the AR pathway in the absence of high circulating levels of androgen plays a critical role in CRPC [7, 8]. It has been suggested that AR signaling in CRPC is sustained by development of AR amplification, mutation, alternate splicing, and several alternative molecular mechanisms [6, 10]. When prostate cancer cells have been adapted to the low androgen environment, β-catenin has been shown to act as a coactivator of AR to enhance AR transcriptional activity not only in the presence of DHT, but also in the presence of androstenedione, a weaker adrenal androgen remaining present in CRPC patients [26, 30, 33]. β-Catenin is also one of the three AR coactivators (other two AR specific coactivators are ARA70 and ARA55) that can enhance AR transcriptional activity in LNCaP cells when treated with 17β-estradiol [26, 30, 33]. In addition, β-catenin can function as a coactivator with altered ARs with mutations W741C and T877A in prostate cancer cell lines [33]. These AR mutations were detected in CRPC patients that have been treated with bicalutamide leading to the W741C mutation and also in CRPC patients with lymph node metastatic lesions containing the T877A mutation [33]. In rodent studies, Chesire et al. [22] reported that castrated mice receiving androgen treatment exhibited nuclear co-localization of AR and β-catenin in normal prostatic epithelium. Nuclear β-catenin localization was found to occur concomitantly with androgen-induced regrowth of normal rat prostate from androgen deprivation induced regression. Furthermore, Wang et al. [20] observed increased expression and nuclear colocalization of AR and β-catenin as well as the interaction between endogenous AR and β-catenin in CRPC from castrated mice. However, they found no interaction or colocalization of AR and β-catenin in xenografts from noncastrated mice. Mutations of β-catenin are uncommon in prostate cancer (< 5%) [59, 60].

Taken together, these results suggested that β-catenin plays an integral role in formation of the androgen-receptor transcriptional complex.
in CRPC. Based on available information, we proposed a simplified relationship between Wnt and AR signaling during prostate cancer development and progression as summarized in Figure 2. AR and Wnt signaling may reinforce each other to elicit specific target genes for promoting androgen-independent growth and progression. As such, β-catenin/AR interactions could have distinct clinical relevance and be a potential therapeutic target for treatment of CRPC, especially working best at low androgens.

The cross-talk between β-catenin and multiple pathways in prostate cancer

Nuclear β-catenin can also arise through other mechanisms besides alterations in the canonical Wnt signaling pathway. In this section we consider examples of the accumulation of β-catenin through other mechanisms. Constitutive protein kinase B (also known as AKT) activation in prostate cancer due to loss of PTEN can inhibit GSK-3β activity leading to stabilization and nuclear accumulation of β-catenin [61]. Liu et al. [62] demonstrated that addition of H2-relaxin to LNCaP cells resulted in increased phosphorylation of protein kinase B (Akt) and phosphorylation of glycogen synthase kinase-3β (GSK-3β) with subsequent cytoplasmic accumulation of β-catenin. This is followed by nuclear translocation, formation of the β-catenin/AR complex and increased AR transcriptional activity in LNCaP cells. Paradoxically, in neuronal cells, Pawlowski et al. [63] demonstrated that ligand-bound AR promoted the accumulation of β-catenin in the nucleus, The nuclear co-localization of AR and β-catenin was independent of the GSK-3β, p42/44 ERK mitogen-activated protein kinase, and phosphatidylinositol 3-kinase pathways. Other groups have shown that GSK-3β can phosphorylate AR and suppress its ability to activate transcription under certain conditions. Wnt pathway activation can stimulate Akt activity which promotes an MDM-2-mediated degradation process that reduces AR protein levels in Wnt-stimulated prostate cancer cells [64, 65].

Adenomatous polyposis coli (APC) is a major regulator of β-catenin protein level through phosphorylation of β-catenin which signals the degradation of β-catenin. Inactivation of APC gene by hypermethylation was detected in prostate cancer but not in normal prostate tissues [66, 67] thereby favoring the accumulation of β-catenin. However, Mulholland et al. [68] reported that AR can promote β-catenin nuclear translocation independently of APC. Pin1 is a peptidyl-prolyl cis/trans isomerase that stabilizes β-catenin by inhibiting its binding to the APC gene product and subsequent GSK-3β-dependent degradation. The expression of Pin1 in radical prostatectomy specimens is strongly correlated with the incidence of recurrence and metastasis [69]. Pin1 stabilizes β-catenin and abrogates the β-catenin and AR
interaction, leading to increased β-catenin/TCF-4 signaling and increased expression of the WNT target genes c-Myc and TCF-4 itself [69]. The result is exclusive to PTEN-deficient LNCaP cells. Protocadherin-PC, localized on the human Y chromosome, was shown to be selectively expressed in apoptosis-resistant and hormone-resistant human prostate cancer cells and tissues [70]. Expression of cytoplasmic protocadherin-PC can induce expression of Wnt target genes through interacting and stabilizing β-catenin [70]. These mechanisms illustrate different means of directing gene regulation involving β-catenin.

Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor that plays an essential role in cellular response to hypoxia. HIF-1α is known to enhance β-catenin activated AR transactivation in hypoxia [71]. During cellular hypoxia, increased expression of complexes composed of HIF-1α, AR and β-catenin in the nucleus were observed and activated androgen responsive genes. Knockdown of HIF-1α attenuated the recruitment of AR and β-catenin to the androgen response elements (AREs) and deactivated activation of androgen-responsive genes [71]. β-Catenin can also interact with FOXO transcriptional factors in response to oxidative stress to promote cells exit from the cell cycle and entry into cell quiescence [72]. FOXA1 was shown to be overexpressed in advanced prostate cancer and metastases, and overexpression of FOXA1 led to enrichment of the Wnt signaling pathway [73]. Heterogeneous nuclear ribonucleoprotein K (HnRNP K) was also found to be overexpressed in prostate cancer tissues and overexpression of HnRNP K positively associated with high Gleason score and poor prognosis [74, 75]. HnRNP K can bind to the β-catenin/TCF-4 complex for regulation of pre-mRNA splicing and some types of alternative splicing have been suggested to promote prostate cancer progression [74, 75]. Finally, β-catenin can also influence the metastatic potential of prostate cancer cells by suppression of transcription of a metastasis suppressor, KAI1, through formation of a β-catenin-reptin chromatin remodeling complex [76].

**TCF family members in prostate cancer**

Despite extensive research, the crosstalks between AR and Wnt/β-catenin signaling pathways remain complex and conflicting. The canonical Wnt pathway is mediated by TCF/LEF-1 transcription factor family members which include TCF-1, TCF-3, TCF-4 and LEF-1 [38]. The human AR gene itself has been shown to be a Wnt target gene [65]. Activation of Wnt/β-catenin signaling by Wnt stimulation can increase AR expression via TCF/LEF-1-binding sites on the AR promoter, leading to upregulation of AR target genes [65]. On the contrary, AR can also compete with TCF/LEF-1 for β-catenin binding and thus inhibit TCF/LEF-1-mediated transcription [77]. Chesire et al. showed that anti-androgens alleviated the AR mediated suppression of TCF transcriptional activity and activation of TCF/LEF-1 inhibited the expression of AR-regulated genes [40, 78]. Other studies demonstrated that there is a direct interaction between the AR DNA binding domain and TCF-4 and that endogenous AR is bound to the TCF responsive element in the MYC promoter [79]. Ectopic expression of TCF-4 by transfection repressed the transcriptional activity of full-length AR, which was only partially attenuated by β-catenin transfection [79]. AR activator of 55 kDa (ARA-55), also named hydrogen peroxide-induced clone 5 (HIC-5), belongs to the paxillin family of LIM proteins and is also a component of the focal adhesion complex [80, 81]. ARA-55 can bind to AR resulting in an increase of AR transcriptional activity and in turn alter ligand specificity of AR [80, 81]. The LIM domain-containing C-terminal half of ARA-55 binds to a conserved alternatively spliced exon in LEF/TCF transcription factor and functions as negative regulator of a subset of LEF/TCF family members [80, 81]. Possible function significance of these different LEF/TCF transcription complexes requires further investigation.

The Lymphoid Enhancer Factor 1 (LEF-1) is another member of TCF/LEF family and also a Wnt target gene [82]. Li and Lee et al. reported that LEF1 mRNA levels are up 100 fold higher in LNCaP AI cells (a CRPC derivative of LNCaP cells) compared to the parental LNCaP cells as determined by a microarray gene expression profiling analysis [82]. LEF-1 expression was associated with increased cell proliferation, migration, and invasion as well as AR expression [82, 83]. LEF-1 is usually expressed in the basal epithelial layer of the urogenital sinus in the human fetal prostate and in the urogenital
mesenchyme and the basal epithelial layer of the urogenital sinus in mouse prostate development. The survival of LEF-1-expressing basal cells was not affected by treatment with the anti-androgen bicalutamide. Moreover LEF-1 can repopulate the luminal compartment following bicalutamide-induced regression of branching morphogenesis in the absence of androgen signaling [84]. This result suggested that LEF-1 may be involved in producing an androgen-independent population of prostate progenitors. TMPRSS2-ERG fusion protein has recently been shown to be reactivated in CRPC [85, 86]. Wu et al. [87] provided evidence that LEF-1 is a critical transcriptional target of the ETS-family transcription factor ERG and that LEF-1 expression is selectively upregulated in TMPRSS2-ERG fusion positive prostate cancer as observed by microarray profiling analysis. The combined results suggested that LEF-1 and Wnt signaling may provide a good novel targets for treatment of prostate cancer patients with TMPRSS2-ERG fusion expression.

Expression profiling and second generation sequencing identifies activation of the Wnt pathway in CRPC

Recent gene expression profiling analyses have allowed for the identification specific molecular signatures that are associated with CRPC. Wang et al. [20] performed affymetrix genechip analysis using LNCaP xenografts and hollow fiber models to identify global changes in gene expression profiling associated with CRPC. They found that the Wnt/β-catenin signaling pathway was one of the major pathways activated in CRPC. Rajan et al. [35] performed RNA sequencing (RNA-seq) profiling on tumour-rich, targeted prostatic biopsies from 7 patients with locally advanced or metastatic prostate cancer before and approximately 22 weeks after ADT. The results showed that 29 (e.g. FZD4, FZD7, JUN, and MMP7) out of 150 genes in the Wnt signalling pathway were upregulated after ADT, which was the top pathway with significantly upregulated genes. In addition, 14 of these upregulated genes were reported in previously published studies on ADT-driven gene expression changes [88, 89]. These data suggested that the Wnt signaling pathway is predominantly upregulated in CRPC.

By using whole-exome sequencing technology to compare castration-resistant and androgen-sensitive matched pairs of prostate cancer xenografts derived from the same site of origin, Kumar et al. [90] found that 86 gene mutations were unique to CRPCs. Among them, there was a significant enrichment of mutations in the components of the Wnt pathway in CRPC tumors, including FZD6, GSK3B and WNT6. Furthermore, Grasso et al. [34] performed whole-exome sequencing on 50 metastatic CRPCs obtained at rapid autopsy (including three different foci from the same patient) and 11 treatment-naive, high-grade localized prostate cancers. They also identified components of the Wnt signaling pathway to be significantly mutated (57 somatic mutations in 38 samples) in CRPC, on the other hand, Wnt pathway alterations were virtually absent in hormone naïve primary prostate cancer. In conclusion, these results suggested that mutations in the Wnt pathway likely emerge during progression or the development of resistance after ADT in prostate cancer.

Wnt paracrine signaling from prostatic stroma affects prostate epithelium in the settings of resistance to ADT or chemotherapy

There are emerging studies indicating that Wnt paracrine signaling from neighboring prostatic stroma cells could affect prostate epithelium during prostate cancer initiation and development of resistance to ADT or chemotherapy [36, 37, 91]. Using a tissue recombination method, Zong et al. [92] showed that high-mobility group AT-hook 2 (HMGA2) overexpressing urogenital sinus mesenchymal (UGSM) promoted multifoci prostatic intraepithelial neoplasia (PIN) in the neighboring naïve epithelium. Co-overexpression of HMGA2 and AR in UGSM cells synergistically induced poorly differentiated prostate adenocarcinoma. Wnt ligands (i.e. WNT2, 4 and 9A) were shown to be the major paracrine factors from HMGA2 overexpressing UGSM. HMGA2-induced PIN formation was strongly inhibited by overexpression of the Wnt antagonists DKK1 and SFRP2, both secreted products. This study suggested that Wnt paracrine signaling may play an important stroma contribution to prostate cancer initiation and progression. In a related study, Li et al. [36] demonstrated that stroma-specific knockout mice for the TGF-β type II receptor expression (Tgfbr2flox/flox) increased the expression of Wnt3a to promote PIN formation and tumorigenesis, and that systemic treatment with Wnt3a neu-
Wnt signaling and castration-resistant prostate cancer

neutralizing antibodies inhibited growth of LNCaP/Tgfbr2^fspoKO xenografts. Placencio et al. [91] from the same group further demonstrated that the prostates of Tgfbr2^fspoKO mice had constitutively active Wnt signaling regardless of androgen status. The prostates of Tgfbr2^fspoKO as well as Tgfbr2^fspoKO prostatic stromal cells/wild-type or SV40 large T antigen expressing epithelia recombinants were resistant to androgen deprivation-mediated regression. These results suggested that the paracrine Wnt signaling from Tgfbr2^fspoKO prostate stroma cells not only facilitated the progression of PIN lesions to adenocarcinoma, but also conferred resistance to the epithelial component to androgen deprivation.

Liu et al. [93] studied the effect of dihydrotestosterone (DHT) on the interactions between preosteoblasts MC3T3 cells and bone metastasis cell line MDA-PCa-2b. They found that DHT exerted more potent growth stimulating effect on MDA-PCa-2b cells via upregulation of Wnt activity in bone cells. The effect was enhanced when the prostate cancer cells were cocultured with preosteoblasts compared to DHT treatment of MDA-PCa-2b cells alone. The enhanced growth of MDA-PCa-2b cells by DHT in this coculture experiment can be blocked by exogenous Wnt antagonists such as DKK-1 and SFRP-1 recombinant proteins. This result indicated a potential role of paracrine Wnt factors from bone cells on prostate cancer cell growth at bone metastatic sites. Sun et al. [37] showed that mitoxantrone and docetaxel therapy induced expression of stromal WNT16B and the elevated expression levels of WNT16B in prostatectomy tissue samples were associated with high risk of cancer recurrence. WNT16B expression in the stroma can also promote epithelial-to-mesenchymal transition (EMT) to increase tumor invasiveness and tumor growth. These findings provided a new mechanism of acquired resistance to chemotherapy drugs that is based on the properties of the tumor microenvironment.

Wnt ligands, receptors, secreted Wnt antagonists in prostate cancer

There are several Wnt receptors that are expressed in normal prostate tissues which includes FZD-1, -4, -6, and -10. Out of these receptors, expression of FZD-4 and FZD-6 were found to be increased in prostate tumors [102-105]. Gupta et al. [106] reported that ERG oncogenic transcriptional factor regulated the expression of FZD-4, which mediated epithelial-to-mesenchymal transition in prostate cancer.
Secreted Wnt antagonists, which include the secreted frizzled-related protein (sFRP) family, Dickkopf (DKK) family, and Wnt inhibitory factor-1 (WIF-1), are negative modulators of Wnt signaling [107-109]. Wnts bind to FZDs via cysteine-rich domain (CRD) sequence with high affinity. Expression of CRD alone can inhibit Wnt/β-catenin signaling [107]. All sFRPs contain a CRD sequence and can inhibit Wnt signaling either by sequestering Wnt ligands or by forming nonfunctional complexes with Frizzled receptors [107]. The Dkk family proteins include DKK-1, -2, -3, and -4 in humans [108]. DKK-1 inhibits Wnt signaling by disrupting the binding of LRP6 to the Wnt/FZD ligand-receptor complex [108]. Although WIF-1 does not share any sequence similarity with the CRD sequence of FZDs and sFRPs, it can also bind to Wnts and inhibit signaling [109]. Down-regulation of sFRPs, DKKs and WIF-1 by gene deletion or promoter hypermethylation are frequently detected in many human cancers including prostate cancer [110-114], suggesting their possible role as tumor suppressors. Endogenous Dkk-3 was found to be required to limit cell proliferation both in the developing mouse prostate and in 3D cultures of human prostate epithelial cells [115]. DKK-3 was further shown to regulate the response of normal prostate epithelial cells to transforming growth factor-β (TGF-β) [116]. These studies are consistent with a model in which DKK-3 is required by normal cells to prevent the TGF-β-dependent switch from tumor suppressor to tumor promoter. In contrast, DKK-1 was shown to promote tumor growth and prostate cancer progression in part by suppression of p21 (CIP1/WAF1) through a mechanism independent of canonical Wnt signaling [117]. DKK-1 also inhibited Wnt induced osteoblastic activity [118]. DKK-1 appears to play a role in parathyroid hormone related protein (PTHrP) induced osteolytic activity and in transition from osteoblastic to osteolytic bone lesions [119]. The sFRP family member sFRP1 was also found to be down-regulated both in prostate cancer tissues and prostate cancer cell lines. sFRP1 can function as a negative regulator of the AR [120]. However, this effect of sFRP1 was not associated with Wnt inhibition [120]. Joesting et al. [121] found that sFRP1 was overexpressed in prostate cancer stromal cells and overexpression of sFRP1 activated JNK pathway, but not the canonical Wnt pathway. Horvath et al. [50] reported that sFRP4 overexpression can decrease cell proliferation, anchorage-independent growth, and invasiveness in PC3 cells. SFRP3/FRZB was the first identified secreted Wnt antagonist during studies of the Spemann’s organizer of Xenopus [122]. Our group has shown that expression of sFRP3/FRZB or WIF-1 in a CRPC cell line PC3 caused a reversal of epithelial-to-mesenchymal transition and inhibition of tumor growth by inhibition of canonical Wnt pathway [123, 124]. Taken together, these results suggested that the role of Wnt ligands and secreted antagonists work in context-dependent manner in different types of cells or by varied ligand-receptor interactions. Wnt ligands and receptors appear to be important in CRPC.

Wnt signaling in disease models of CRPC

In transgenic mouse models, conditionally deleted exon3 of β-catenin resulted in production of high-grade PIN (HG-PIN) and induction of Foxa2 re-expression in the adult mouse prostate through Wnt/β-catenin signaling as well as promoting prostate growth even under the conditions of androgen deprivation [125]. In mouse models with the SV40 large T-antigen, which inactivates p53 and Rb [126], or in mice expressing mutated K-ras and form invasive carcinoma [127], or in mice with loss of PTEN expression [128], β-catenin overexpression can promote highly invasive prostate cancer and squamous metaplasia, even in the absence of androgens. These findings provided strong evidence for a critical role of the Wnt/β-catenin signaling in prostate cancer development and progression.

In xenograft mouse models, H2 relaxin (RLN2) was shown to facilitate castrate-resistant growth of prostate cancer cells through AKT phosphorylation-mediated activation of both the Wnt/β-catenin and the AR pathway [129]. As mentioned before Hic-5/ARA55 is a co-factor for both TCF/LEFs and AR and can inhibit the Wnt/β-catenin pathway [36]. Overexpression of HIC-5/ARA55 in LNCaP cells can restore sensitivity of xenograft composed of LNCaP cells and Tgfbr2-KO fibroblasts to androgen deprivation-induced tumor regression [130]. In an orthotopic C4-2B CRPC xenograft mouse model, Placentino et al. [131] found that mesenchymal stem cells (MSCs) were recruited into tumor sites and were associated with enhanced tumor growth. The result occurs with
activation of Wnt signaling. When MSCs were used as a targeted delivery vector for the exoge-
ously expressed sFRP2, tumor growth was reduced and the response to androgen depriva-
tion was restored. These animal and tissue cul-
ture studies suggested that components of the
Wnt signaling pathway may be involved in pros-
tate cancer progression to more invasive phe-
notype and contributed to castration resis-
tance.

**Therapeutic potentials of targeting Wnt/β-
catenin in CRPC and future directions**

Although, the results remain inconclusive,
β-catenin nuclear localization as well as its
co-localization with AR has been more fre-
quently observed in CRPC compared to hor-
mone naïve prostate cancer. Alterations in mul-
tiple signaling pathways, including PI3K/AKT,
HIF-1α, PIN1, APC gene silencing and more
have been shown to cause nuclear localization
of β-catenin and activation of Wnt signaling.
Moreover, β-catenin acts as an AR co-factor to
enhance androgen-stimulated AR transcription-
al activation and increase sensitivity to low le-
vels of androgens and to non-androgen ligands.
As a result, the interaction between β-catenin
and AR in CRPC may elicit specific target genes
for promoting androgen-independent growth
and progression. The next-generation sequenc-
ing technology (i.e. whole-exome and RNA
sequencing) has revealed that the Wnt pathway
is one of the top signaling pathways that were
frequently mutated or genomically altered in
lethal CRPC patients. Likewise, paracrine Wnt
signaling also contributed to resistance to ADT
after chemotherapy and androgen deprivation
therapy.

In addition to high expression in cancer cells,
Wnt/β-catenin signaling is highly activated in
cancer stem cells (CSCs) [132]. Prostate CSCs
are suggested to be resistant to androgen
depression therapy and responsible for cancer recurrence [133]. Targeting CSCs by inhibition
of the Wnt pathway may have the potential to
reduce the self-renewal and aggressive behav-
ior of prostate cancer [134]. As a proof of prin-
cle, Lee et al. [135] demonstrated that a novel
compound that disrupts both β-catenin/TCF
and β-catenin/AR protein interactions can
inhibit prostate tumor growth in a xenograft
model and also blocked bicalutamide-resistant
sphere-forming cells. This study indicated the
potential of targeting the β-catenin/AR as a
good treatment target for CRPC.

As described in this review, the Wnt signaling
pathway plays a complex role in CRPC. Given
the multiple important roles of Wnt signaling in
CRPC, the Wnt signaling pathway can not be
ignored as a source of therapeutic targets.
Inhibition of the Wnt pathway would allow thera-
pies to target not only epithelial cells but also
stromal cells, as well as, CSCs, androgen-depe-
dent, and androgen-independent prostate can-
cer cells. Future therapies for CRPC would most
likely benefit from combination of both anti-
androgens and Wnt inhibitors.

**Acknowledgements**

We apologize for not being able to cite all of
the publications in the field due to the limitations
of the length of the review. NY is supported by
DOD grant W81XWH-13-1-0257. XZ is support-
ed by UCI ICTS pilot grant, DOD grant
W81XWH-11-1-0312 and NIH grants R01C-
A122558 and R21CA152804.

**Disclosure of conflict of interest**

None.

**Address correspondence to:** Xiaolin Zi, Department
of Urology, University of California, Irvine, 101 The
City Drive South, Rt. 81 Bldg. 55 Rm. 302, Orange
CA 92868, USA. Tel: 714-456-8316; Fax: 714-456-
1786; E-mail: xzi@uci.edu

**References**

[1] Siegel R, Naishadham D, Jemal A. Cancer sta-
tistics, 2013. CA Cancer J Clin 2013; 63: 11-
30.

[2] Sakr WA, Grignon DJ, Crissman JD, Heilbrun
LK, Cassin BJ, Pontes JJ, Haas GP. High grade
prostatic intraepithelial neoplasia (HGPIN) and
prostatic adenocarcinoma between the ages of
20-69: an autopsy study of 249 cases. In

BJ, Nilsson S. Postoperative radiotherapy after
prostatectomy--a review. Scand J Urol Nephrol
2003; 37: 10-5.

of detectable PSA levels after radical pros-
tectomy--a review. Scand J Urol Nephrol
2003; 37: 10-5.

prostatic carcinoma. Early versus late endo-

Wnt signaling and castration-resistant prostate cancer


[14] Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice vari-
Wnt signaling and castration-resistant prostate cancer


[70] Thompson VC, Hurtado-Coll A, Turbin D, Fazli L, Lehman ML, Gleave ME, Nelson CC. Relaxin drives Wnt signaling through upregulation of
PCDHY in prostate cancer. Prostate 2010; 70: 1134-45.


Wnt signaling and castration-resistant prostate cancer


[135] Lee E, Madar A, David G, Garabedian MJ, Das-gupta R, Logan SK. Inhibition of androgen receptor and β-catenin activity in prostate can-

Wnt signaling and castration-resistant prostate cancer